Orally Disintegrating Tablet Market Size, Share, and Industry Analysis, By Drug Type (Anti-psychotics, Anti-epileptics, Anti-hypertensives, Anxiolytics, Anti-allergic Drugs, Proton Pump Inhibitors, and Others), By Indication (Neurological Diseases, Cardiovascular Diseases, Gastrointestinal Diseases, Allergic Diseases, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Orally disintegrating tablets (ODT) refer to the solid dosage forms designed to enhance a pharmaceutical product's disintegration and dissolution rates. These tablets are also called orodispersible tablets, mouth-dissolving tablets, quick-disintegrating tablets, fast-disintegrating tablets, fast-dissolving tablets, porous tablets, rapid-dissolving tablets, and rapimelts.

ODT is ideal for patients who have difficulties with swallowing mechanisms. They are particularly suitable for geriatric and pediatric patients or those suffering from conditions such as dysphagia. The growing geriatric population is suffering from a wide range of medical conditions, such as cardiovascular diseases and neurological diseases, and has difficulties in swallowing, which are some of the factors driving the market growth throughout the forecast period.

• For instance, as per the data provided by the World Health Organization (WHO) in October 2022, nearly one in six people in the world will be aged 60 years or over by the end of 2023. The number of population aged 60 years and above will increase from 1 billion in 2020 to 1.4 billion by 2030. The number of people aged 80 years and above is also expected to triple between 2020 and 2050, with 426 million.

The pharmaceutical industry is experiencing a growth in the demand for fast-acting drugs. ODTs are an ideal solution, as they allow the active ingredients to be absorbed quickly through the oral mucosa, resulting in a rapid onset of the therapeutic effects. This is especially paramount for the treatment of conditions, such as migraines or allergies, where immediate relief is often necessary. Additionally, the growing initiatives by the key industry layers for the development of orally disintegrating tablets (ODT) to treat a wide range of diseases is one of the additional factors driving the market growth.

The COVID-19 pandemic had a positive impact on the orally disintegrating tablets market in 2020. The market witnessed a growing demand for orally disintegrating tablets during the pandemic. This is majorly due to the fact that the COVID-19 infection increased the risk for neurological diseases such as migraines, depression, anxiety, and cardiovascular diseases, including stroke. Therefore, the pandemic hastened the adoption of orally disintegrating tablets for the treatment of several diseases linked with the COVID-19 infection. Thus, this has contributed to increased sales of ODTs in some regions. Furthermore, key stakeholders in the market collaborated to enter into agreements to develop novel orally disintegrating tablets.

• In June 2022, Catalent and the Israel-based biopharmaceutical firm MigVax announced a development agreement for the utilization of the Zydis Bio orally disintegrating tablet (ODT) technology for the administration of the COVID-19 vaccine, MigVax-101.

Segmentation

Key Insights

The following key insights are covered in the report:

• Prevalence of Key Diseases, By Key Countries, 2022/2023
• Pipeline Analysis By Key Players
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, and Partnerships) By Key Players
• Impact of COVID-19 on the Market

Analysis by Indication

Based on the indication, the market can be segmented into neurological diseases, cardiovascular diseases, gastrointestinal diseases, allergic diseases, and others.

The neurological diseases segment is anticipated to hold a significant market share during the forecast period due to the rising prevalence of central nervous system (CNS) related disorders. Furthermore, the increasing efforts by the key industry players to receive regulatory approval for the development and launches of orally disintegrating tablets is another factor contributing to the segmental growth throughout the forecast period.

• For instance, in March 2023, Zydus Group received the U.S. Food and Drug Administration (FDA) approval for the manufacturing and marketing of the Olanzapine orally disintegrating tablets used in the treatment of central nervous system disorders, including schizophrenia and bipolar disorder.

Moreover, the cardiovascular diseases segment is projected to grow at a considerable CAGR during the forecast period. The increasing prevalence of cardiovascular diseases across the globe is one of the main reasons for the segmental growth.

• For instance, according to the WORLD HEART REPORT 2023, more than half a billion individuals globally were affected by cardiovascular diseases by the end of 2021.

Furthermore, the gastrointestinal diseases segment held a considerable market share in 2023, mainly due to the increasing regulatory approvals for the launches of orally disintegrating tablets used in the treatment of gastrointestinal diseases, such as peptic ulcers, acidity, hyperacidity, and others.

• For example, in March 2024, Dr. Reddy’s Laboratories Ltd. announced that it had received approval from the Central Drugs Standard Control Organization (CDSCO) for the manufacturing and marketing of Omeprazole delayed-release orally disintegrating tablets in the Indian market.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the orally disintegrating tablet market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant market share in 2023 and is expected to exhibit a significant CAGR throughout the forecast period. The market growth in this region is mainly due to several pharmaceutical manufacturers, such as Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited, and others. These players are engaged in the development of orally disintegrating tablet formulations.

In addition, the rising prevalence of diseases related to the central nervous and cardiovascular systems has triggered several pharmaceutical companies to develop effective medicines that can be administered with ease. Also, the increasing regulatory approvals for orally disintegrating tablets offering faster medicinal effects for a wide range of diseases is one of the additional factors contributing to the market growth in this region.

• For instance, in December 2021, the U.S. Food and Drug Administration (FDA) approved glycopyrrolate orally disintegrating tablets, Dartisla ODT, manufactured by Edenbridge Pharmaceuticals to reduce the symptoms of a peptic ulcer and as an adjunct to treatment of peptic ulcers.

Furthermore, the Asia Pacific region accounted for a considerable market share in 2023 and is anticipated to grow at a substantial CAGR throughout the forecast period. The regional growth is primarily attributed to numerous factors, such as the affordability of orally disintegrating tablets due to their cost-effectiveness compared to the other dosage forms. Moreover, there is a rising awareness among healthcare professionals and patients about the benefits and usefulness of orally disintegrating tablets, which is further contributing to their adoption in this region.

Key Players Covered

The report includes the profiles of key players, such as Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories Ltd., Amring Pharmaceuticals Inc., Lilly, Pfizer Inc., and Novartis AG.

Key Industry Developments

• In July 2023, Aenova Group and Galvita AG entered into a partnership to advance the development, formulation, and production of oral dosage forms, including orally disintegrating tablets.
• In February 2022, Amring Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) approval of its generic Lamotrigine ODT, a generic equivalent of Lamictal. The company also began commercializing this product in the U.S. market.
• In November 2021, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced their partnership for the commercialization of Rimegepant (Nurtec) orally disintegrating tablets outside the U.S. This drug is used for the treatment of episodic migraine in adults.
• In February 2021, Dr. Reddy’s Laboratories Ltd. introduced the orally disintegrating tablets Lansoprazole DR, a therapeutically equivalent generic version of Prevacid SoluTab delayed-release orally disintegrating tablets in the U.S. market.
• In June 2019, Kissei Pharmaceutical Co., Ltd. announced the launch of GLUBES combination oral disintegrating tablet, a rapid-acting insulin secretagogue and agent for postprandial hyperglycemia.